A new bedtime nasal spray could reduce the severity of obstructive sleep apnoea (OSA) in people and lower their blood pressure, according to new Australian research published in The Journal of Heart and Circulatory Physiology.
The potassium channel blocker nasal spray works by increasing the activity of the muscles that keep the upper airway open, and reducing the likelihood of the throat collapsing during sleep.
In a blind trial, seven out of 10 people who were given the nasal spray showed a reduction in the frequency of episodic upper airway collapse during sleep and lower blood pressure the next morning.
"These insights provide a potential pathway for development of new therapeutic solutions for those people with OSA who are unable to tolerate CPAP machines and/or upper airway surgery," Professor Danny Eckert, College of Medicine and Public Health, said.
The above article was sent to subscribers in Pharmacy Daily's issue from 18 Mar 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Mar 24
